COIOSDeep risk insights through multi-disciplinary research across the globe
the shadow of a building on the side of it
Item new Preprint · not peer-reviewed Added

Treating drug-resistant TB contacts up to age 45 was modelled as cost-effective

A model of 189 countries found that offering preventive treatment to household contacts of drug-resistant tuberculosis up to age 45, rather than only under-15s, was cost-effective in 160 countries.

Levofloxacin preventive treatment for household contacts of drug-resistant tuberculosis was modelled in 189 countries, with age-dependent risks of progression, death and side effects. Extending treatment from under-15s to age 45 was cost-effective in 160 countries, at a cost per healthy year gained below 30% of income per head. Treating contacts of all ages would avert 9,960 deaths globally, but result in 71,000 serious side effects.

Why it is interesting: Treating without a test for infection averted more and cost less than testing contacts first.

Source
medRxiv, 2 October 2026
Paper
Household contact management of drug-resistant tuberculosis: a global cost-effectiveness modelling analysis of expanded preventive treatment by age
Authors
Mafirakureva N, McQuaid CF, Harker M, Garcia-Prats A, Hesseling AC, Seddon JA et al.
DOI
10.64898/2026.10.01.26364489
Type
Preprint
Design
Decision-analytic cost-effectiveness model of MDR/RR-tuberculosis household contact management in 189 countries, by age band
Verdict
New finding
Driver
Value in health
Abstract — the authors' own words, CC BY

Background

Tuberculosis preventive treatment (TPT) with levofloxacin reduces tuberculosis disease incidence in multidrug-resistant or rifampicin-resistant (MDR/RR)-tuberculosis household contacts. However, with age, disease progression risk falls and the frequency of adverse events (AE) rises. Methods

To inform decision-makers, we evaluated the cost-effectiveness of expanding the use of MDR/RR-TPT by age, with and without tests of tuberculosis infection. We modelled MDR/RR-household contact management (HHCM) in 189 countries, incorporating age-dependent risks of disease progression, death and AEs. Incremental cost-effectiveness ratios were calculated as USD/disability-adjusted life year (DALY) averted, and as a fraction of per capita gross domestic product (GDP). Findings

Compared to baseline of MDR/RR-HHCM with TPT for those Interpretation

Expanding MDR/RR-TPT use to older ages without testing appears cost-effective in most settings, but may require substantial resources and result in large numbers of AEs. Funding

Unitaid

Other drivers in Data, models and systems